Skip to main content
. 2019 Sep 1;9(9):1905–1921.

Figure 6.

Figure 6

TRAIL or interferons synergized with ANA to inhibit cancer cell growth. A. Effects of IFN-α on SLFN12 mRNA expression. Bel7404 cells were stimulated with IFN-α (3000 IU/mL) for indicated time periods and the SLFN12 mRNA expression was measured by Quantitative Real-Time PCR. B. Effects of ANA or ANA+ IFN-α on the growth of Bel7404 cells. Bel7404 cells were stimulated with IFN-α (3000 IU/mL), ANA (100 nM), or a combination of the two and the cell growths were analyzed by RTCA. C. Effects of IFN-α, ANA or ANA+ IFN-α on cell death. Bel7404 cells were treated with IFN-α (3000 IU/mL), ANA (100 nM), or a combination of the two, and the cell death were analyzed by immunoblotting for PARP cleavage. The anti-tubulin antibody was used as a control for equal protein loading. D. Effects of SLFN12 siRNA-knockdown on the IFN-α and ANA combination treatment. The Bel7404 cells were transfected with either a control siRNA or the SLFN12 siRNA for 24 hours, then the siRNA-transfected H4 cells were cultured with ANA (100 nM) plus IFN-α or DMSO and the growth of the cells were measured by RTCA. E. Effects of TNF-α or TRAIL on the ANA-induced cell growth inhibition. The Bel7404 cells were treated with TNF-α (10 ng/mL), ANA, or a combination of TNF-α and ANA. The cell growths were monitored by the RTCA analyzer. F. Effects of TRAIL on the ANA-induced cell growth inhibition. The Bel7404 cells were treated with TRAIL (100 ng/mL), ANA, or a combination of TRAIL and ANA. The cell growths were monitored by the RTCA analyzer.